It has been recently documented that PI3K inhibitors were the most effective in inhibiting leukemic cell proliferation and survival in a panel of T-ALL human cell lines, irrespectively of PTEN status. The gene discussed is PTEN; the disease is acute lymphoblastic leukemia.